Axsome Therapeutics, Inc. (AXSM) Stock Price & Analysis
Axsome Therapeutics, Inc. (AXSM) rose 4.47% to USD 245.64 as of June 9, 2026 at 23:50 UTC, according to Nexqual real-time market data.
AXSM last closed at USD 235.14; the session ranged USD 236.38–246.41 on volume of 870,329 shares. Market capitalization is $12.64B, with a 52-week range of USD 96.09–246.41 (NGM). Source: Nexqual, June 9, 2026 at 23:50 UTC.
Key Statistics (as of June 9, 2026 at 23:50 UTC)
| Price | USD 245.64 |
|---|---|
| Change | ▲ 4.47% (up) |
| Previous Close | USD 235.14 |
| Open | USD 237.21 |
| Day Range | USD 236.38 – 246.41 |
| 52-Week Range | USD 96.09 – 246.41 |
| Volume | 870,329 shares |
| Market Cap | $12.64B |
| Exchange | NGM |
Technical Analysis (AXSM)
Nexqual's technical model rates AXSM "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.44 (overbought) |
| vs SMA50 | Above (USD 206.39) |
| MACD | 8.08 (positive) |
Analyst Ratings (AXSM)
Wall Street analysts rate AXSM "Strong Buy" based on 21 analysts, with a mean price target of USD 270.28 (range USD 200–328.81), per Nexqual as of June 9, 2026 at 23:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 270.28 |
| High Target | USD 328.81 |
| Low Target | USD 200 |
| Buy / Hold / Sell | 20 / 1 / 0 |
Earnings (AXSM)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD -0.82 |
| Revenue Estimate | $222.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.26 vs est -0.86 ▼ miss |
| 2025-12-31 | USD -0.56 vs est -0.73 ▲ beat |
| 2025-09-30 | USD -0.94 vs est -0.9 ▼ miss |
| 2025-06-30 | USD -0.97 vs est -1.09 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:50 UTC.
Financials & Fundamentals (AXSM)
| Total Revenue | $708.24M |
|---|---|
| Revenue Growth (YoY) | +57.40% |
| Gross Margin | +92.60% |
| Operating Margin | -32.83% |
| Profit Margin | -26.59% |
| ROE | -349.38% |
| Debt / Equity | 402.84 |
| Current Ratio | 1.39 |
| Total Cash | $305.11M |
| Total Debt | $219.90M |
| Free Cash Flow | $-3.85M |
Source: Nexqual, June 9, 2026 at 23:50 UTC.
Financial Health Score (AXSM)
Nexqual rates Axsome Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:50 UTC.
| Growth | Strong — Revenue +66% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 93%, operating -33% |
| Balance Sheet | Critical — $305M cash vs $220M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -349%, ROA -16.8% |
Ownership (AXSM)
| Insider Ownership | +15.34% |
|---|---|
| Institutional Ownership | +76.51% |
| Shares Outstanding | 51.46M |
| Float | 43.56M |
| Short % of Float | +9.41% |
Source: Nexqual, June 9, 2026 at 23:50 UTC.
Leadership (AXSM)
Axsome Therapeutics, Inc. is led by Herriot Tabuteau (age 57), Founder, Chairman, CEO & President, per Nexqual as of June 9, 2026 at 23:50 UTC.
| Founder, Chairman, CEO & President | Herriot Tabuteau (age 57) |
|---|---|
| Chief Financial Officer | Nick Pizzie (age 50) |
| Chief Operating Officer | Mark L. Jacobson M.A. (age 42) |
| Director of Corporate Communications | Darren Opland |
Major Backers & Investors (AXSM)
Notable institutional backers of Axsome Therapeutics, Inc. include FMR, LLC, Price (T.Rowe) Associates Inc, Invesco, according to Nexqual as of June 9, 2026 at 23:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 3.05% |
| Price (T.Rowe) Associates Inc | 2.56% |
| Invesco | 2.52% |
| Wellington Management | 2.23% |
| Deep Track Capital, Lp | 2.14% |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 0.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.42% |
| BlackRock | 9.49% |
| Geode Capital | 2.26% |
| State Street | 1.92% |
Source: Nexqual, June 9, 2026 at 23:50 UTC.
From Axsome Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
- It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TGTX | TG Therapeutics, Inc. | USD 43.37 | ▲ 7.99% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 476.89 | ▼ 2.07% |
| AUPH | Aurinia Pharmaceuticals Inc | USD 15.78 | ▼ 0.38% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 3.88 | ▼ 8.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:50 UTC. This page is informational and not investment advice.